Wall Street analysts expect that Sierra Oncology Inc (NASDAQ:SRRA) will post ($0.19) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Sierra Oncology’s earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.23). Sierra Oncology reported earnings of ($0.20) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 5%. The business is expected to report its next earnings report on Tuesday, February 26th.

According to Zacks, analysts expect that Sierra Oncology will report full-year earnings of ($0.75) per share for the current year, with EPS estimates ranging from ($0.80) to ($0.71). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.72) per share, with EPS estimates ranging from ($0.78) to ($0.66). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Sierra Oncology.

Sierra Oncology (NASDAQ:SRRA) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03).

Several analysts have recently weighed in on SRRA shares. Zacks Investment Research downgraded Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, August 15th. ValuEngine downgraded Sierra Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, October 2nd.

NASDAQ:SRRA traded up $0.06 during mid-day trading on Friday, hitting $1.66. The company had a trading volume of 331,561 shares, compared to its average volume of 549,299. The company has a debt-to-equity ratio of 0.05, a current ratio of 14.68 and a quick ratio of 14.68. Sierra Oncology has a 1 year low of $1.48 and a 1 year high of $4.09. The firm has a market capitalization of $121.22 million, a PE ratio of -1.98 and a beta of 1.73.

Several institutional investors have recently made changes to their positions in SRRA. JPMorgan Chase & Co. grew its stake in Sierra Oncology by 91,592.6% in the first quarter. JPMorgan Chase & Co. now owns 221,896 shares of the biotechnology company’s stock worth $459,000 after purchasing an additional 221,654 shares in the last quarter. Fred Alger Management Inc. acquired a new position in Sierra Oncology in the second quarter worth about $246,000. 683 Capital Management LLC grew its stake in Sierra Oncology by 3.5% in the second quarter. 683 Capital Management LLC now owns 1,800,000 shares of the biotechnology company’s stock worth $5,328,000 after purchasing an additional 60,926 shares in the last quarter. Millennium Management LLC grew its stake in Sierra Oncology by 86.6% in the first quarter. Millennium Management LLC now owns 2,280,430 shares of the biotechnology company’s stock worth $4,720,000 after purchasing an additional 1,058,574 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in Sierra Oncology in the second quarter worth about $3,799,000. Institutional investors own 64.30% of the company’s stock.

Sierra Oncology Company Profile

Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.

See Also: Index Funds

Get a free copy of the Zacks research report on Sierra Oncology (SRRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.